Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A
Health Services Research Unit, University of Aberdeen, UK.
Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. doi: 10.3310/hta10450.
The aim of this study was to determine the clinical effectiveness and cost-effectiveness of laparoscopic, laparoscopically assisted (hereafter together described as laparoscopic surgery) and hand-assisted laparoscopic surgery (HALS) in comparison with open surgery for the treatment of colorectal cancer.
Electronic databases were searched from 2000 to May 2005. A review of economic evaluations was undertaken by the National Institute for Health and Clinical Excellence in 2001. This review was updated from 2000 until July 2005.
Data from selected studies were extracted and assessed. Dichotomous outcome data from individual trials were combined using the relative risk method and continuous outcomes were combined using the Mantel-Haenszel weighted mean difference method. Summaries of the results from individual patient data (IPD) meta-analyses were also presented. An economic evaluation was also carried out using a Markov model incorporating the data from the systematic review. The results were first presented as a balance sheet for comparison of the surgical techniques. It was then used to estimate cost-effectiveness measured in terms of incremental cost per life-year gained and incremental cost per quality-adjusted life-year (QALY) for a time horizon up to 25 years.
Forty-six reports on 20 studies [19 randomised controlled trials (RCTs) and one IPD meta-analysis] were included in the review of clinical effectiveness. The RCTs were of generally moderate quality with the number of participants varying between 16 and 1082, with 10 having less than 100 participants. The total numbers of trial participants who underwent laparoscopic or open surgery were 2429 and 2139, respectively. A systematic review of four papers suggested that laparoscopic surgery is more costly than open surgery. However, the data they provided on effectiveness was poorer than the evidence from the review of effectiveness. The estimates from the systematic review of clinical effectiveness were incorporated into a Markov model used to estimate cost-effectiveness for a time horizon of up to 25 years. In terms of incremental cost per life-year, laparoscopic surgery was found to be more costly and no more effective than open surgery. With respect to incremental cost per QALY, few data were available to differentiate between laparoscopic and open surgery. The results of the base-case analysis indicate that there is an approximately 40% chance that laparoscopic surgery is the more cost-effective intervention at a threshold willingness to pay for a QALY of pound 30,000. A second analysis assuming equal mortality and disease-free survival found that there was an approximately 50% likelihood at a similar threshold value. Broadly similar results were found in the sensitivity analyses. A threshold analysis was performed to investigate the magnitude of QALY gain associated with quicker recovery following laparoscopic surgery required to provide an incremental cost per QALY of pound 30,000. The implied number of additional QALYs required would be 0.009-0.010 compared with open surgery.
Laparoscopic resection is associated with a quicker recovery (shorter time to return to usual activities and length of hospitalisation) and no evidence of a difference in mortality or disease-free survival up to 3 years following surgery. However, operation times are longer and a significant number of procedures initiated laparoscopically may need to be converted to open surgery. The rate of conversion may be dependent on experience in terms of both patient selection and performing the technique. Laparoscopic resection appears more costly to the health service than open resection, with an estimated extra total cost of between pound 250 and pound 300 per patient. In terms of relative cost-effectiveness, laparoscopic resection is associated with a modest additional cost, short-term benefits associated with more rapid recovery and similar long-term outcomes in terms of survival and cure rates up to 3 years. Assuming equivalence of long-term outcomes, a judgement is required as to whether the benefits associated with earlier recovery are worth this extra cost. The long-term follow-up of the RCT cohorts would be very useful further research and ideally these data should be incorporated into a wider IPD meta-analysis. Data on the long-term complications of surgery such as incisional hernias and differences in outcomes such as persisting pain would also be valuable. Once available, further data on both costs and utilities should be included in an updated model. At this point, further consideration should then be given as to whether additional data should be collected within ongoing trials. Few data were available to assess the relative merits of HALS. Ideally, there should be more data from methodologically sound RCTs. Further research is needed on whether the balance of advantages and disadvantages of laparoscopic surgery varies within subgroups based on the different stages and locations of disease. Research relating to the effect of experience on performance is also required.
本研究旨在确定与开腹手术相比,腹腔镜手术、腹腔镜辅助手术(以下统称为腹腔镜手术)及手辅助腹腔镜手术(HALS)治疗结直肠癌的临床疗效和成本效益。
检索了2000年至2005年5月的电子数据库。2001年英国国家卫生与临床优化研究所进行了一项经济评估综述。该综述从2000年更新至2005年7月。
提取并评估所选研究的数据。采用相对危险度法合并各试验的二分类结局数据,采用Mantel-Haenszel加权均数差法合并连续性结局数据。还呈现了个体患者数据(IPD)荟萃分析结果的总结。使用纳入系统评价数据的马尔可夫模型进行经济评估。结果首先以资产负债表形式呈现,用于比较手术技术。然后用于估计在长达25年的时间范围内,以每获得一个生命年的增量成本和每获得一个质量调整生命年(QALY)的增量成本衡量的成本效益。
临床疗效综述纳入了20项研究的46篇报告[19项随机对照试验(RCT)和1项IPD荟萃分析]。RCT的质量一般中等,参与者数量在16至1082之间,其中10项研究的参与者少于100人。接受腹腔镜手术或开腹手术的试验参与者总数分别为2429人和2139人。对四篇论文的系统评价表明,腹腔镜手术比开腹手术成本更高。然而,他们提供的有效性数据比有效性综述的证据更差。临床有效性系统评价的估计值被纳入一个马尔可夫模型,用于估计长达25年时间范围内的成本效益。就每生命年的增量成本而言,发现腹腔镜手术比开腹手术成本更高且效果并不更好。关于每QALY的增量成本,几乎没有数据可用于区分腹腔镜手术和开腹手术。基础病例分析结果表明,在每QALY支付意愿阈值为30000英镑时,腹腔镜手术更具成本效益的可能性约为40%。在假设死亡率和无病生存率相等的二次分析中,发现在类似阈值下可能性约为50%。敏感性分析得出了大致相似的结果。进行了阈值分析,以研究与腹腔镜手术后更快恢复相关的QALY增加幅度,以提供每QALY 30000英镑的增量成本。与开腹手术相比,所需额外QALY的隐含数量为0.009 - 0.010。
腹腔镜切除术与更快恢复相关(恢复正常活动的时间和住院时间更短),且术后3年内无死亡率或无病生存率差异的证据。然而,手术时间更长,大量最初采用腹腔镜手术的病例可能需要转为开腹手术。转换率可能取决于患者选择和技术操作方面的经验。与开腹切除术相比,腹腔镜切除术对医疗服务而言成本似乎更高,估计每位患者额外总成本在250英镑至300英镑之间。就相对成本效益而言,腹腔镜切除术伴随着适度的额外成本、与更快恢复相关的短期益处以及长达3年的生存和治愈率方面相似的长期结局。假设长期结局相同,则需要判断早期恢复带来的益处是否值得这一额外成本。对RCT队列进行长期随访将是非常有用的进一步研究,理想情况下,这些数据应纳入更广泛的IPD荟萃分析。关于手术长期并发症如切口疝以及持续疼痛等结局差异的数据也将很有价值。一旦获得,成本和效用的进一步数据应纳入更新后的模型。此时,应进一步考虑是否应在正在进行的试验中收集更多数据。几乎没有数据可用于评估HALS的相对优点。理想情况下,应该有更多来自方法学上合理的RCT的数据。需要进一步研究腹腔镜手术的利弊平衡是否因疾病的不同阶段和部位在亚组中有所不同。还需要开展与经验对手术操作影响相关的研究。